Director
Christian Rommel, Ph.D.
Christian Rommel, Ph.D., has served on our Board of Directors since May 2024. He is currently the Executive Vice President, Global Head of Research & Development, and a Member of the Executive Committee at Bayer Pharmaceuticals, a division of Bayer AG (BAYN). He joined Bayer in February 2021, bringing extensive experience from his prior role as Senior Vice President, Global Head of Oncology, Pharma Research and Early Development at Roche, where he worked from January 2018 to February 2021. Before that, Dr. Rommel held significant roles at Amgen Inc. (AMGN), including Vice President of External Research and Development and Vice President of Research Oncology.
Earlier in his career, Dr. Rommel served as Chief Scientific Officer at Intellikine, Inc., a biopharmaceutical company, from its inception through its acquisition by Takeda Pharmaceutical Company (TAK). He also held leadership and scientific positions at Merck Serono and Regeneron Pharmaceuticals Inc. (REGN)
Dr. Rommel earned his Ph.D. in molecular oncology from the Max Planck Institute in Berlin, Germany, and the Institute of Medical Virology at the University of Zurich, Switzerland. He is also a lecturer in biotechnology at ETH Zurich, Switzerland. He has authored over 70 publications, including papers in Science and Nature, and holds 18 patents.
